Proprotein Convertase Subtilisin/Kexin Type 9 and Systemic Inflammatory Biomarker Pentraxin 3 for Risk Stratification Among STEMI Patients Undergoing Primary PCI

References

• Tang Y, Li SL, Hu JH, et al. Research progress on alternative non-classical mechanisms of PCSK9 in atherosclerosis in patients with and without diabetes. Cardiovasc Diabetol. 2020;19(1):33. doi:10.1186/s12933-020-01009-4
   PubMed Web of Science ®Google Scholar
• Ferri N, Marchianò S, Tibolla G, et al. PCSK9 knock-out mice are protected from neoin- timal formation in response to perivascular carotid collar placement. Atherosclerosis. 2016;253:214–224. doi:10.1016/j.atherosclerosis.2016.07.910
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–1722. doi:10.1056/NEJMoa1615664
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097–2107. doi:10.1056/NEJMoa1801174
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Leiter LA, Wiviott SD, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(12):941–950. doi:10.1016/S2213-8587(17)30313-3
   PubMed Web of Science ®Google Scholar
• Goodman AR, Cardozo T, Abagyan R, et al. Long pentraxins: an emerging group of proteins with diverse functions. Cytokine 4 Growth Factor Rev. 1996;7:191–202. doi:10.1016/1359-6101(96)00019-6
   PubMedGoogle Scholar
• Rolph MS, Zimmer S, Bottazzi B, et al. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2002;22:e10–4. doi:10.1161/01.ATV.0000015595.95497.2F
   PubMed Web of Science ®Google Scholar
• Kimura S, Sugiyama T, Hishikari K, et al. Relationship of systemic pentraxin-3 values with coronary plaque components on optical coherence tomography and post-percutaneous coronary intervention outcomes in patients with stable angina pectoris. Atherosclerosis. 2020;292:127–135. doi:10.1016/j.atherosclerosis.2019.11.022
   PubMed Web of Science ®Google Scholar
• Uetani T, Amano T, Harada K, et al. Impact of insulin resistance on post-procedural myocardial injury and clinical outcomes in patients who underwent elective coro- nary interventions with drug-eluting stents. JACC Cardiovasc Interv. 2012;5(11):1159–1167. doi:10.1016/j.jcin.2012.07.008
   PubMed Web of Science ®Google Scholar
• Fiorentino TV, Marini MA, Succurro E, et al. Relationships of surrogate indexes of insulin resistance with insulin sensitivity assessed by euglycemic hyperinsulinemic clamp and subclinical vascular damage. BMJ Open Diabetes Res Care. 2019;7(1):e911. doi:10.1136/bmjdrc-2019-000911
   PubMed Web of Science ®Google Scholar
• Du T, Yuan G, Zhang M, et al. Clinical usefulness of lipid ratios, visceral adiposity indicators, and the triglycerides and glucose index as risk markers of insulin resistance. Cardiovasc Diabetol. 2014;13:146. doi:10.1186/s12933-014-0146-3
   PubMed Web of Science ®Google Scholar
• Yurtseven E, Ural D, Baysal K, Tokgözoğlu L. An update on the role of PCSK9 in atherosclerosis. J Atheroscler Thromb. 2020;27(9):909–918. doi:10.5551/jat.55400
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Puri R, Anderson T, et al. Effect of evolocumab on coronary plaque composition. J Am Coll Cardiol. 2018;72(17):2012–2021. doi:10.1016/j.jacc.2018.06.078
   PubMed Web of Science ®Google Scholar
• Sun J, Lepor NE, Cantón G, et al. Serial magnetic resonance imaging detects a rapid reduction in plaque lipid content under PCSK9 inhibition with alirocumab. Int J Cardiovasc Imaging. 2021;37(4):1415–1422. doi:10.1007/s10554-020-02115-w
   PubMed Web of Science ®Google Scholar
• Koga S, Ikeda S, Yoshida T, et al. Elevated levels of systemic pentraxin 3 are associated with thin-cap 9 fibroatheroma in coronary culprit lesions: assessment by optical coherence tomography 10 and intravascular ultrasound. JACC Cardiovasc Interv. 2013;6:945–954.
   PubMed Web of Science ®Google Scholar
• Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119–177.
   PubMed Web of Science ®Google Scholar
• Stevens PE, Levin A; Kidney disease: improving global outcomes chronic kidney disease guideline development work group, M. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158(11):825–830. doi:10.7326/0003-4819-158-11-201306040-00007
   PubMed Web of Science ®Google Scholar
• Tearney GJ, Regar E, Akasaka T, et al. Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. J Am Coll Cardiol. 2012;59(12):1058–1072. doi:10.1016/j.jacc.2011.09.079
   PubMed Web of Science ®Google Scholar
• Tian J, Ren X, Vergallo R, et al. Distinct morphological features of ruptured culprit plaque for acute coronary events compared to those with silent rupture and thin-cap fibroatheroma: a combined optical coherence tomography and intravascular ultrasound study. J Am Coll Cardiol. 2014;63(21):2209–2216. doi:10.1016/j.jacc.2014.01.061
   PubMed Web of Science ®Google Scholar
• Prati F, Regar E, Mintz GS, et al. Expert review document on methodology, terminology, and clinical applications of optical coherence tomography: physical principles, methodology of image acquisition, and clinical application for assessment of coronary arteries and atherosclerosis. Eur Heart J. 2010;31:401–415. doi:10.1093/eurheartj/ehp433
   PubMed Web of Science ®Google Scholar
• Vecchie A, Bonaventura A, Meessen J, et al. PCSK9 is associated with mortality in patients with septic shock: data from the ALBIOS study. J Intern Med. 2021;289(2):179–192. doi:10.1111/joim.13150
   PubMed Web of Science ®Google Scholar
• Casula M, Montecucco F, Bonaventura A, et al. Update on the role of Pentraxin 3 in atherosclerosis and cardiovascular diseases. Vascul Pharmacol. 2017;99:1–12. doi:10.1016/j.vph.2017.10.003
   PubMed Web of Science ®Google Scholar
• Liu S, Qu X, Liu F, et al. Pentraxin 3 as a prognostic biomarker in patients with systemic inflammation or infection. Mediators Inflamm. 2014;2014:421429. doi:10.1155/2014/421429
   PubMed Web of Science ®Google Scholar
• Muller B, Peri G, Doni A, et al. Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med. 2001;29:1404–1407. doi:10.1097/00003246-200107000-00017
   PubMed Web of Science ®Google Scholar
• Bastrup-Birk S, Munthe-Fog L, Skjoedt MO, et al. Pentraxin-3 level at admission is a strong predictor of short-term mortality in a community-based hospital setting. J Intern Med. 2015;277:562–572. doi:10.1111/joim.12294
   PubMed Web of Science ®Google Scholar
• Rannikko J, Jacome Sanz D, Ortutay Z, et al. Reduced plasma PCSK9 response in patients with bacteraemia is associated with mortality. J Intern Med. 2019;286:553–561. doi:10.1111/joim.12946
   PubMed Web of Science ®Google Scholar
• Mauri T, Bellani G, Patroniti N, et al. Persisting high levels of plasma pentraxin 3 over the first days after severe sepsis and septic shock onset are associated with mortality. Intensive Care Med. 2010;36:621–629. doi:10.1007/s00134-010-1752-5
   PubMed Web of Science ®Google Scholar
• Lambert G, Charlton F, Rye K-A, et al. Molecular basis of PCSK9 function. Atherosclerosis. 2009;203:1–7. doi:10.1016/j.atherosclerosis.2008.06.010
   PubMed Web of Science ®Google Scholar
• Lagace TA. PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells. Curr Opin Lipidol. 2014;25:387–393.
   PubMed Web of Science ®Google Scholar
• Norata GD, Garlanda C, Catapano AL. The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases. Trends Cardiovasc Med. 2010;20:35–40. doi:10.1016/j.tcm.2010.03.005
   PubMed Web of Science ®Google Scholar
• Parlak A, Aydoğan U, Iyisoy A, et al. Elevated pentraxin-3 levels are related to blood pressure levels in hypertensive patients: an observational study. Anadolu Kardiyol Derg. 2012;12:298–304.
   PubMed Web of Science ®Google Scholar
• Presta M, Camozzi M, Salvatori G, et al. Role of the soluble pattern recognition receptor PTX3 in vascular biology. J Cell Mol Med. 2007;11:723–738. doi:10.1111/j.1582-4934.2007.00061.x
   PubMed Web of Science ®Google Scholar
• Navarese EP, Kolodziejczak M, Schulze V, et al. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic r eview and meta-analysis. Ann Intern Med. 2015;163:40–51. doi:10.7326/M14-2957
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Wiviott SD, et al; Open-Label Study of Long-TermEvaluation against LDL Choles terol (OSLER) Investigators. Efficacy and safety of evolocumab in r educing lipids and cardiovascular events. N Engl J Med. 2015;372:1500–1509. doi:10.1056/NEJMoa1500858
   PubMed Web of Science ®Google Scholar
• Robinson JG, Farnier M, Krempf M, et al; ODYSSEY LONGTERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 372;2015:1489–1499. doi:10.1056/NEJMoa1501031
   PubMed Web of Science ®Google Scholar
• Ferri N, Tibolla G, Pirillo A, et al. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. Atherosclerosis. 2012;220:381–386. doi:10.1016/j.atherosclerosis.2011.11.026
   PubMed Web of Science ®Google Scholar
• Tang Z, Jiang L, Peng J, et al. PCSK9 si RNA suppresses the inflammatory response induced b yoxLDL through inhibition of NF-κB activation in THP-1-derivedmacrophages. Int J Mol Med. 2012;30:931–938. doi:10.3892/ijmm.2012.1072
   PubMed Web of Science ®Google Scholar
• Volanakis JE, Narkates AJ. Interaction of C-reactive protein with artificial phosphatidylcholine bilayers and complement. J Immunol. 1981;126:1820–1825.
   PubMed Web of Science ®Google Scholar
• Maekawa Y, Nagai T, Anzai A. Pentraxins: CRP and PTX3 and cardiovascular disease. Inflamm Allergy Drug Targets. 2011;10(4):229–235. doi:10.2174/187152811796117744
   PubMedGoogle Scholar
• Momtazi-Borojeni AA, Sabouri-Rad S, Gotto AM, et al. PCSK9 and inflammation: a review of experimental and clinical evidence. Eur Heart J Cardiovasc Pharmacother. 2019;5(4):237–245. doi:10.1093/ehjcvp/pvz022
   PubMed Web of Science ®Google Scholar
• Li S, Zhang Y, Xu R-X, et al. Proprotein convertase subtilisin-kexin type 9 as a biomarker for the severity of coronary artery disease. Ann Med. 2015;47:386–393.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhu C-G, Xu R-X, et al. Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery disease. J Clin Lipidol. 2014;8:494–500.
   PubMed Web of Science ®Google Scholar
• Gencer B, Montecucco F, Nanchen D, et al. Prognostic value of PCSK9 levels in patients with acute coronary syndromes. Eur Heart J. 2016;37:546–553.
   PubMedGoogle Scholar
• Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med. 1992;326:242–250. doi:10.1056/NEJM199201233260406
   PubMed Web of Science ®Google Scholar
• Yahagi K, Kolodgie FD, Lutter C, et al. Pathology of human coronary and carotid artery atherosclerosis and vascular calcification in diabetes mellitus. Arterioscler Thromb Vasc Biol. 2017;37:191–204. doi:10.1161/ATVBAHA.116.306256
   PubMed Web of Science ®Google Scholar
• Mather AN, Crean A, Abidin N, et al. Relationship of dysglycemia to acute myocardial infarct size and cardiovascular outcome as determined by cardiovascular magnetic resonance. J Cardiovasc Magn Resonan. 2010;12:61. doi:10.1186/1532-429X-12-61
   PubMed Web of Science ®Google Scholar
• Kim HO, Kim CJ, Kurihara O, et al. Angiographic features of patients with coronary plaque erosion. Int J Cardiol. 2019;288:12–16. doi:10.1016/j.ijcard.2019.03.039
   PubMed Web of Science ®Google Scholar
• Hu S, Zhu Y, Zhang Y, et al. Management and outcome of patients with acute coronary syndrome caused by plaque rupture versus plaque erosion: an Intravascular Optical Coherence Tomography Study. J Am Heart Assoc. 2017;6:004730.
   Web of Science ®Google Scholar
• Schulz R, Schluter KD, Laufs U. Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9). Basic Res Cardiol. 2015;110:4. doi:10.1007/s00395-015-0463-z
   PubMed Web of Science ®Google Scholar
• Li S, Guo Y-L, Xu R-X, et al. Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease. Atherosclerosis. 2014;234:441–445. doi:10.1016/j.atherosclerosis.2014.04.001
   PubMed Web of Science ®Google Scholar
• Pearson TA, Mensah GA, Hong Y, et al. CDC/AHA workshop on markers of inflammation and cardiovascular disease. Circulation. 2004;110:e543–e544.
   PubMed Web of Science ®Google Scholar
• Danesh J, Lewington S, Thompson SG, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant metaanalysis. JAMA. 2005;294:1799–1809.
   PubMed Web of Science ®Google Scholar
• Du Clos TW. Function of C-reactive protein. Ann Med. 2000;32:274–278. doi:10.3109/07853890009011772
   PubMed Web of Science ®Google Scholar
• Zhang Y, Cliff W, Schoefl G, et al. Coronary C-reactive protein distribution: its relation to development of atherosclerosis. Atherosclerosis. 1999;145:375–379. doi:10.1016/S0021-9150(99)00105-7
   PubMed Web of Science ®Google Scholar
• Kaptoge S, Di Angelantonio E, Lowe G, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375:132–140.
   PubMed Web of Science ®Google Scholar
• Ding Z, Liu S, Wang X, et al. Hemodynamic shear stress via ROS modulates PCSK9 expression in human vascular endothelial and smooth muscle cells and along the mouse aorta. Antioxid Redox Signal. 2015;22:760–771. doi:10.1089/ars.2014.6054
   PubMed Web of Science ®Google Scholar
• Brandes RP, Kreuzer J. Vascular NADPH oxidases: molecular mechanisms of activation. Cardiovasc Res. 2005;65:16–27. doi:10.1016/j.cardiores.2004.08.007
   PubMed Web of Science ®Google Scholar
• Reyes-Sofer G, Pavlyha M, Ngai C, et al. Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans. Circulation. 2017;135(4):352–362. doi:10.1161/CIRCULATIONAHA.116.025253
   PubMed Web of Science ®Google Scholar
• Kastelein JJP, Akdim F, Stroes ESG, et al; for the ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 358;2008:1431–1443. doi:10.1056/NEJMoa0800742
   PubMed Web of Science ®Google Scholar
• Jenny NS, Arnold AM, Kuller LH, Tracy RP, Psaty BM. Associations of pentraxin 3 with cardiovascular disease and all-cause death: the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 2009;29:594–599.
   PubMed Web of Science ®Google Scholar
• Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002;90:251–262. doi:10.1161/res.90.3.251
   PubMed Web of Science ®Google Scholar
• Volpe M, Iaccarino G, Vecchione C, et al. Association and cosegregation of stroke with impaired endothelium dependent vasorelaxation in stroke prone, spontaneously hypertensive rats. J Clin Invest. 1996;98:256–261. doi:10.1172/JCI118787
   PubMed Web of Science ®Google Scholar
• Peri G, Introna M, Corradi D, et al. PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation. 2000;102:636–641. doi:10.1161/01.CIR.102.6.636
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhao X, Zhou P, et al. Plasma Pentraxin-3 combined with plaque characteristics predict cardiovascular risk in ST-segment elevated myocardial infarction: an Optical Coherence Tomography Study. J Inflamm Res. 2021;14:4409–4419. doi:10.2147/JIR.S330600
   PubMed Web of Science ®Google Scholar
• Vancraeynest D, Pasquet A, Roelants V, et al. Imaging the vulnerable plaque. J Am Coll Cardiol. 2011;57:1961. doi:10.1016/j.jacc.2011.02.018
   PubMed Web of Science ®Google Scholar
• Nebuloni M, Pasqualini F, Zerbi P, et al. PTX3 expression in the heart tissues of patients with myocardial infarction and infectious myocarditis. Cardiovasc Pathol. 2011;20:e27–35. doi:10.1016/j.carpath.2010.02.005
   PubMedGoogle Scholar
• Savchenko A, Imamura M, Ohashi R, et al. Expression of pen-traxin 3 (PTX3) in human atherosclerotic lesions. J Pathol. 2008;215:48–55. doi:10.1002/path.2314
   PubMed Web of Science ®Google Scholar
• Norata GD, Marchesi P, Pulakazhi Venu VK, et al. Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atheroscle-rosis. Circulation. 2009;120:699–708. doi:10.1161/CIRCULATIONAHA.108.806547
   PubMed Web of Science ®Google Scholar